RY 107
Alternative Names: BDR-762; RY-107Latest Information Update: 30 Jun 2022
At a glance
- Originator MDimune; Reyon Pharmaceutical
- Developer MDimune
- Class Gene therapies
- Mechanism of Action Gene transference; Protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Unspecified
Most Recent Events
- 23 Jun 2022 MDimune has patent protection for BioDrone® in USA, Europe, Japan, Korea and China before June 2022 (MDimune pipeline, June 2022)
- 23 Jun 2022 Early research in Unspecified in South Korea (parenteral) before June 2022 (MDimune pipeline, June 2022)
- 31 Dec 2021 MDimune collaborates with Reyon Pharmaceutical to develop RY 107 for rare genetic disorders (MDimune pipeline, June 2022)